Third Arc Bio is a clinical-stage biotechnology company headquartered in Lower Gwynedd, Pennsylvania, developing multifunctional antibodies that build immune synapses to precisely activate or inhibit T cells. Its ARCStim platform targets solid tumors and its ARCTag platform pursues tissue-specific precision immune regulation for immunology and inflammation (I&I) indications; lead program ARC101 is a bispecific T-cell engager in a Phase 1 trial in patients with CLDN6-expressing solid tumors. The company launched in 2022 with seed financing from Omega Funds, raised an oversubscribed $165M Series A, and closed a $52M Series A extension in February 2026 with Andreessen Horowitz joining the syndicate. Third Arc Bio publishes no public API, developer portal, SDK or machine-readable specification — it is a therapeutics developer, not a software vendor.
Third Arc Bio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Therapeutics, Antibodies, and Oncology.
Third Arc Bio’s developer surface includes engineering blog, support, and 6 more developer resources.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: third-arc-bio
name: Third Arc Bio
description: Third Arc Bio is a clinical-stage biotechnology company headquartered in Lower Gwynedd, Pennsylvania, developing
multifunctional antibodies that build immune synapses to precisely activate or inhibit T cells. Its ARCStim platform targets
solid tumors and its ARCTag platform pursues tissue-specific precision immune regulation for immunology and inflammation
(I&I) indications; lead program ARC101 is a bispecific T-cell engager in a Phase 1 trial in patients with CLDN6-expressing
solid tumors. The company launched in 2022 with seed financing from Omega Funds, raised an oversubscribed $165M Series A,
and closed a $52M Series A extension in February 2026 with Andreessen Horowitz joining the syndicate. Third Arc Bio publishes
no public API, developer portal, SDK or machine-readable specification — it is a therapeutics developer, not a software
vendor.
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source:
- security
generated: '2026-09-02'
method: derived
image: https://thirdarcbio.com/thirdarc-og-image.png
url: https://raw.githubusercontent.com/api-evangelist/third-arc-bio/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment-pass-no-api-surface
specificationVersion: '0.20'
created: '2026-08-30'
modified: '2026-08-30'
tags:
- Company
- Biotechnology
- Therapeutics
- Antibodies
- Oncology
- Immunology
- Life Sciences
- Clinical Stage
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/third-arc-bio-domain-security.yml
- type: Website
url: https://thirdarcbio.com/
- type: PrivacyPolicy
url: https://thirdarcbio.com/privacy-policy/
- type: TermsOfService
url: https://thirdarcbio.com/terms-of-service/
- type: Blog
url: https://thirdarcbio.com/news/
- type: Support
url: mailto:info@thirdarcbio.com
- type: LinkedIn
url: https://www.linkedin.com/company/third-arc-bio/
- type: LLMsTxt
url: llms/third-arc-bio-llms.txt
x-enrichment:
date: '2026-08-30'
status: minimal
artifacts_added: 3
pass: local-v1
x-coverage:
state: none
reason: not-a-software-company
detail: Third Arc Bio is a clinical-stage antibody therapeutics developer; thirdarcbio.com is a Gatsby static marketing
site with only science, pipeline, team, news and policy pages, and every contract-discovery path (/openapi.json, /swagger.json,
/api-docs, /docs, /developers, /api, /graphql, /llms.txt) plus every /.well-known/ document returns the site's 404 body,
while api., developer., docs. and mcp. subdomains do not resolve in DNS.
evidence:
- url: https://thirdarcbio.com/
status: 200
- url: https://thirdarcbio.com/openapi.json
status: 404
- url: https://thirdarcbio.com/developers
status: 404
- url: https://thirdarcbio.com/.well-known/agent-card.json
status: 404
- url: https://thirdarcbio.com/.well-known/api-catalog
status: 404
checked: '2026-08-30'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.